Participated · Seed · Apr 2026

Founded in 2024 by Yisroel Wahl, OrahVision is developing a software-first platform that uses AI and voice guidance to help people with low vision access printed and digital text. Its product lets users place documents or books in view of a camera and receive AI-enhanced audio narration, visual explanation, and interactive assistance. The platform is designed to run on standard devices such as personal computers and tablets rather than requiring specialized hardware. OrahVision moved from a foundational prototype to early product development informed by initial user feedback. The company secured roughly $20,000 in external pre-seed funding (closed October 20, 2025) alongside an earlier approximately $30,000 backer investment, and counts AngelMD and Keiretsu Forum among participating investors. OrahVision intends to use funds for further feature refinement, user testing, community outreach, and to position itself for larger fundraising and pilot partnerships in 2026.

Led · Seed · Nov 2024

OraQ AI is a Calgary, Canada-based healthtech startup that offers an AI-driven clinical decision support platform for dental practices. Its platform analyzes patient records to provide risk assessments across seven areas: medical risk, sleep disorders, gum health, bite and jaw issues, cracks and teeth, cavity profiles, and esthetics. Founded in 2021 by Dr. Amreesh Khanna, Dr. Mike Parchewsky, and Wayne Madhlangobe, the company aims to empower dentists to make standardized, evidence-based decisions. OraQ plans to expand across North America with a focus on small dental offices. Financially, the company secured CA$2.6M in seed funding in November 2024. The capital will be used to fuel growth, enhance practice management features, and drive revenue opportunities for dental practices.

Led · Seed · Sep 2018

Raydiant Oximetry is a venture-backed, clinical-stage medical device company based in San Ramon, California, focused on improving outcomes for mothers and babies during childbirth. The company was founded by Neil P. Ray, MD, and has developed Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a vacuum-induced surgical tool for OB/GYN applications. Raydiant’s core product work centers on fetal pulse oximetry to better identify fetal distress and potentially avoid medically unnecessary C-sections. The company plans to use prize funding and development sprints to further advance and de-risk its technologies for clinical adoption. Raydiant frames its innovations as transformative for monitoring practices during labor and delivery and is advancing through clinical-stage development and expert evaluation. Raydiant Oximetry, based in San Ramon, CA and founded by Neil P. Ray, develops two clinical-stage technologies: Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a surgical device to quantify blood loss, treat uterine atony and prevent postpartum hemorrhage after C-section. The company is focused on improving outcomes for mothers and babies during childbirth. Raydiant plans to use its new funding to support two clinical studies of Lumerah and Daisy being conducted at Eastern Virginia Medical School under Dr. George Saade. The studies aim to generate clinical evidence to validate performance and safety in labor and delivery settings. Raydiant is pursuing regulatory and clinical pathways typical for medical devices as it advances these technologies through clinical evaluation. The company recently raised extension funding to advance those clinical programs. Raydiant Oximetry is a clinical-stage medical device company based in San Ramon, CA focused on improving women’s and neonatal health. Its core product is LUMERAH™, a non-invasive fetal oximeter designed to detect fetal distress during labor and delivery. LUMERAH is an investigational medical device and is not currently approved for commercial sale. The company is led by founder and CEO Neil Ray, MD. Raydiant raised $5M in a Series A2 financing and intends to use the funds to complete a clinical study at the University of Texas Medical Branch in Galveston. The UTMB study, with Dr. George Saade as principal investigator, is part of clinical research supported by the NIH Maternal‑Fetal‑Medicine Network to advance validation of the device. Raydiant Oximetry is a Mountain View, California medical device company that has developed a noninvasive fetal monitor to directly measure a baby’s oxygenation during pregnancy and childbirth. Founded in 2016 and led by CEO Dr. Neil P. Ray, the company is in residence at the Fogarty Institute for Innovation. It has demonstrated feasibility of the technology in pregnant women through an IRB‑approved study and validated results in animal models. Raydiant holds two issued patents protecting the core technology and expects up to ten more patents over the next 36 months. The company raised $1M in seed funding and intends to use the proceeds to build a subsequent prototype with improved accuracy and reliability.

Led · Equity · Aug 2017

Access Vascular manufactures intravenous catheters from a proprietary hydrophilic biomaterial called MIMIX™ that is engineered to mimic the body’s natural chemistry and evade the foreign body response. Its FDA-cleared products include HydroPICC®, HydroPICC® Dual, and HydroMID®, and the MIMIX material is patented. Preclinical and retrospective data presented by the company show a six-fold decrease in complications compared with standard polyurethane catheters, a four-log reduction in bacterial adhesion in an in vitro blood loop model, and a 96% reduction in thrombus accumulation in tested models. The company positions its technology as a way to lower the substantial costs and patient harms associated with vascular access complications. Access Vascular plans to use new funding to ramp production capacity for MIMIX-based devices, to pursue further research into lowering catheter infection rates, and to expand its product portfolio. Leadership frames the technology as poised to transform the standard of care for vascular access. Access Vascular has developed a proprietary hydrophilic, lubricious biomaterial and incorporated it into two commercial venous access devices: the HydroPICC Peripherally Inserted Central Catheter and the HydroMID Midline Catheter. In vitro (and referenced in vivo) studies reported an average 97% reduction in thrombus accumulation on its material versus standard polyurethane catheters. The company was founded in 2015 and is headquartered in Bedford, Mass. Current commercial products are on the market while the company pursues additional clinical and post-market data generation. Planned uses for new capital include generating post-market data on its two devices, expanding its device portfolio, and commercializing that expanded portfolio. The company targets reductions in infection, thrombosis and phlebitis through long-term thrombus-resistant biomaterials. Access Vascular, founded in 2015 by CEO James Biggins, develops intravenous catheters and ports from patented biomaterials that are biocompatible and intended to provide long-term infection protection. Its materials and devices are designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma. The company's first product, the FDA-cleared HydroPICCTM, began commercial use in early 2019. Future applications cited include midlines, dialysis catheters, ports, and other devices. The company intends to expand its portfolio of reduced-thrombosis intravenous devices through continued product development. It plans to use new funding to launch HydroPICC and to initiate its first post-market registry study. Access Vascular is a Bedford, MA–based medical device company developing venous access devices intended to eliminate thrombotic risk. Its lead product, the HydroPICC™, is a peripherally inserted central catheter that has shown in lab testing a reduction in platelet accumulation and therefore thrombosis risk. The company's pipeline includes midlines, a dialysis catheter and ports, all at various stages of development. Access Vascular plans to use the newly raised funds to support submission of a 510(k) application later this year for the HydroPICC. The company raised $3.7M in financing and is led by founder, president and CEO James Biggins. Backers include individual investors and AngelMD, an investment platform and marketplace connecting medical startups, physicians, investors and industry partners.

Led · Equity · Jun 2017

VICIS develops advanced football helmets engineered to reduce the effects of collisions through a soft outer shell and several layered protective systems. Its flagship Zero1 adult helmet retails for $950 and was developed after $20 million of R&D over three years with athletes, engineers and neuroscientists. With the new $28.5M Series B, the company is launching its first helmet specifically for youth players, priced at $495. The youth model is tuned for the impact velocities expected in youth play, weighs under 4 pounds, and offers the widest field of view among kids' helmets. VICIS frames the launch around safety needs for roughly 2 million U.S. youth football players and cites sports as the cause of 21% of traumatic brain injuries annually. The company plans to expand its technology into other sports and has a contract to provide a tailored version of its helmet to the U.S. Army and Marine Corps. VICIS is a Seattle-based sports-technology company focused on developing highly engineered football helmets to improve protection and performance. Its flagship product, the ZERO1, was shaped by leading athletes, engineers, and neurosurgeons and ranked first in the 2017 NFL/NFLPA Helmet Laboratory Performance Testing. The company announced an additional $10 million in funding to support the ZERO1's commercial launch to NCAA and NFL fields in fall 2017, bringing total capital raised to nearly $40 million. The round was led by Harry Fath and a syndicate of sports-medicine physicians investing via the angelMD platform and included over 25 investors; historical backers named in the announcement include prominent spine and neurological surgeons, current and former NFL players, the Peregrine Group, W Fund, Alliance of Angels, and Trilogy Equity Partners. Since being made available in spring, players across the NFL have used the ZERO1 during organized team activities, and VICIS reported exceptional initial feedback and player adoption. CEO and co-founder Dave Marver said the new funding will allow the company to continue investing in technologies that protect athletes and elevate performance. Vicis develops the ZERO1 football helmet, a multilayer product engineered to improve impact absorption and deliver an anatomically optimized fit. The helmet resulted from more than two years of development in close collaboration with elite equipment managers and athletic trainers. It was slated to be available to select NFL and NCAA teams in the spring and worn in competition during the 2016/17 season. The company was co-founded in 2013 by Per Reinhall, Samuel Browd, and Dave Marver, bringing mechanical engineering, pediatric neurosurgery, and medical-technology industry expertise. Vicis intends to use its financing to commercialize the helmet and, after launching with NFL and NCAA programs, plans to expand into high school, youth, and other sports.